Reply to Dorgham et al., “Considering Personalized Interferon Beta Therapy for COVID-19”
- 18 March 2021
- journal article
- letter
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (4)
- https://doi.org/10.1128/aac.00083-21
Abstract
We read with great interest the comments by Dorgham et al regarding to our recently published article.…This publication has 14 references indexed in Scilit:
- Considering Personalized Interferon Beta Therapy for COVID-19Antimicrobial Agents and Chemotherapy, 2021
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signalingSignal Transduction and Targeted Therapy, 2020
- The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19Frontiers in Immunology, 2020
- The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathwayVirus Research, 2020
- A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19Antimicrobial Agents and Chemotherapy, 2020
- Impaired type I interferon activity and inflammatory responses in severe COVID-19 patientsScience, 2020
- Activation and evasion of type I interferon responses by SARS-CoV-2Nature Communications, 2020
- Type I interferons in host defence and inflammatory diseasesLupus Science & Medicine®, 2019
- Systematic review with meta‐analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearanceAlimentary Pharmacology & Therapeutics, 2018
- Sensitivity of SARS/MERS CoV to Interferons and Other Drugs Based on Achievable Serum Concentrations in HumansInfectious Disorders - Drug Targets, 2014